Matches in Wikidata for { <http://www.wikidata.org/entity/Q95284493> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q95284493 description "article scientifique publié en 2020" @default.
- Q95284493 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q95284493 description "scientific article published on 19 May 2020" @default.
- Q95284493 description "wetenschappelijk artikel" @default.
- Q95284493 description "наукова стаття, опублікована 19 травня 2020" @default.
- Q95284493 name "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 name "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 type Item @default.
- Q95284493 label "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 label "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 prefLabel "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 prefLabel "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 P1433 Q95284493-ED641F66-F7CC-472C-B759-58BCF5DD3C50 @default.
- Q95284493 P1476 Q95284493-6DBDB0DA-C7C7-4DEF-99A0-68370E044C9A @default.
- Q95284493 P2093 Q95284493-50D148DB-E3EB-4A6F-AB0D-DBB8C38DF70D @default.
- Q95284493 P2093 Q95284493-7A903813-5B5A-4E92-8312-BA03EBFCFD4A @default.
- Q95284493 P2093 Q95284493-B3CC291A-2529-47E3-AA6B-468FF53FE6C4 @default.
- Q95284493 P2093 Q95284493-BC658593-1E23-4D23-AA6E-E37D4127FAED @default.
- Q95284493 P2093 Q95284493-EA54E8BD-8D66-4A15-ACC8-1EEB0A9D3415 @default.
- Q95284493 P31 Q95284493-82AFA49C-A2A5-42F1-8E72-0A7BEA52F4D5 @default.
- Q95284493 P356 Q95284493-9CD9AB30-C1C7-43E8-92DA-F8E0576EA181 @default.
- Q95284493 P50 Q95284493-E29BD24F-C445-4D17-8994-D918F41913D3 @default.
- Q95284493 P577 Q95284493-459EE7A4-DDE0-4183-AD35-CBB65077B759 @default.
- Q95284493 P698 Q95284493-F9FA97D7-0922-41F4-A3A5-CD343C10AED0 @default.
- Q95284493 P932 Q95284493-3779745A-E7A4-4D46-A4B4-731329231AEF @default.
- Q95284493 P356 IZAA108 @default.
- Q95284493 P698 32426829 @default.
- Q95284493 P1433 Q15749161 @default.
- Q95284493 P1476 "Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients" @default.
- Q95284493 P2093 "Andrea Portocarrero-Castillo" @default.
- Q95284493 P2093 "Deepika Chona" @default.
- Q95284493 P2093 "Jennifer Hellmann" @default.
- Q95284493 P2093 "Michael J Rosen" @default.
- Q95284493 P2093 "Phillip Minar" @default.
- Q95284493 P31 Q13442814 @default.
- Q95284493 P356 "10.1093/IBD/IZAA108" @default.
- Q95284493 P50 Q60318185 @default.
- Q95284493 P577 "2020-05-19T00:00:00Z" @default.
- Q95284493 P698 "32426829" @default.
- Q95284493 P932 "7957223" @default.